Navigation Links
BioNanomatrix Founder and CSO Dr. Han Cao Awarded Chinese Rising Star Entrepreneur Award
Date:10/7/2010

PHILADELPHIA, Oct. 7 /PRNewswire/ -- BioNanomatrix, Inc., which is developing and commercializing breakthrough single-molecule genomic analysis technology, announced today that Founder and Chief Scientific Officer, Han Cao, Ph.D., was awarded the Chinese Rising Star Entrepreneur Award at the China International Economic and Technical Cooperation Forum in Beijing, China on September 27, 2010.  The award is in recognition of Dr. Cao's entrepreneurial spirit and success in the founding of BioNanomatrix and the development of the Company's novel genomic analysis technology.  

Commenting on the milestone, Edward L. Erickson BioNanomatrix's president and chief executive officer, said: "This is a very great honor for Han and for the company he founded, BioNanomatrix.  We believe that the largest country markets for our products are the USA and China, with China rapidly becoming a world leader in genomics and life science research generally.  We look forward to mutually beneficial collaboration with Chinese research institutions and scientists as we commercialize our revolutionary technology."

About BioNanomatrix

BioNanomatrix, Inc., a privately held genomics company, is developing and commercializing game-changing, proprietary technologies for analysis of large biological molecules, such as nucleic acids that are extremely important in life science research, clinical diagnostic applications, and development of new therapeutics.  This technology is designed to reduce dramatically the time and complexity to analyze the genome.  BioNanomatrix's products will provide users with the means to perform single-molecule analyses on minute biological samples that are essentially impossible, impractical or too expensive with current technology.  For more information, visit: www.bionanomatrix.com.

Note: NANOANALYZER is a registered trademark of BioNanomatrix, Inc. The names of other companies, other entities, products and/or services mentioned herein may be the trademarks of their respective owners. Media Contact:  Tiberend Strategic Advisors, Inc. (212) 827-0020 Farrell Denbyfdenby@tiberendstrategicadvisors.com   orAndrew Mielach amielach@tiberendstrategicadvisors.com  
'/>"/>

SOURCE BioNanomatrix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
2. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
3. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
4. BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers
5. BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer
6. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
7. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
8. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
9. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
10. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
11. Scripps Research Institute Highlights Groundbreaking Work of aTyr Pharma Scientific Co-Founder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 Venture ... by a MichBio member organization. They provide an opportunity to interact with peers, make ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
Breaking Biology Technology:
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
Breaking Biology News(10 mins):